Momenta Pharmaceuticals Initiates Phase 1 Trial of M281, an Anti-FcRn Monoclonal Antibody Life Science Investing
Bristol-Myers Squibb to Present New Data Demonstrating Continued Research Expansion and Immuno-Oncology Advancements Across Multiple Blood Cancers at the 21st Congress of the European Hematology Association Pharmaceutical Investing
Teva Gains Recommendation for Approval from FDA Advisory Committees for VANTRELA™ ER (hydrocodone bitartrate) Extended-Release Tablets CII Formulated with Proprietary Abuse Deterrence Technology Life Science Investing
Veloxis to Present Company Overview and Envarus® XR (tacrolimus extended-release tablets) Launch Update at Jefferies 2016 Healthcare Conference Life Science Investing
Chimerix to Participate in Panel on North Carolina’s Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium Life Science Investing
CoLucid Pharmaceuticals Announces Last Patient Randomized in SAMURAI Phase 3 Pivotal Trial of Lasmiditan in Migraine Life Science Investing
Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology Life Science Investing
Advantis Corp. Announces Relationship With Major Hemp/CBD Manufacturer Out of Colorado Life Science Investing
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG) Life Science Investing
